Although oral inhalers have been mass produced for more than 50 years, there is a large body of literature in which evidence has been provided that patients either misuse their inhalers inadvertently or deliberately, thereby reducing their intended efficacy or, in the worst cases, rendering them altogether ineffective. In general, inhalers are becoming increasingly complicated with the incorporation of add-on devices, miniaturized electronics and ever more complex mechanical systems that aid aerosol delivery to the lower respiratory tract and, at the same time provide user feedback. However, these benefits often come at a significant cost, and there are signs that increasing attention will need to be given to the cost-benefit equation in the future. This review explores the development of pressurized metered-dose inhalers, dry powder inhalers and devices for liquid-droplet dispersal and inhalation from the perspective of the patient, by focusing on aspects that improve user interaction. These include designed-in features, such as breath-enhanced or breath-actuated operation that interact with the breathing pattern of the user, as well as more direct feedback aids that confirm, to the patient or healthcare provider that the dose has been delivered and that the patient has inhaled.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1586/17434440.6.2.147 | DOI Listing |
BMJ
December 2024
Safeway Pharmacy, Lynden, Washington, WA, USA.
J Phys Chem A
January 2025
School of Chemistry, University of Bristol, Bristol BS8 1TS, U.K.
In both nature and industry, aerosol droplets contain complex mixtures of solutes, which in many cases include multiple inorganic components. Understanding the drying kinetics of these droplets and the impact on resultant particle morphology is essential for a variety of applications including improving inhalable drugs, mitigating disease transmission, and developing more accurate climate models. However, the previous literature has only focused on the relationship between drying kinetics and particle morphology for aerosol droplets containing a single nonvolatile component.
View Article and Find Full Text PDFBMJ
December 2024
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02120, USA.
Objective: To compare the effectiveness and safety of budesonide-glycopyrrolate-formoterol, a twice daily metered dose inhaler, and fluticasone-umeclidinium-vilanterol, a once daily dry powder inhaler, in patients with chronic obstructive pulmonary disease (COPD) treated in routine clinical practice.
Design: New user cohort study.
Setting: Longitudinal commercial US claims data.
Arch Dis Child
December 2024
Newcastle University Translational and Clinical Research Institute, Newcastle upon Tyne, UK.
Objective: To determine the incidence and describe the presentation and management of unexpected symptomatic glucocorticoid-induced adrenal suppression (AS) in children and young people aged 0-15 years.
Setting And Design: Surveillance study of symptomatic glucocorticoid (GC)-induced AS with supportive biochemical evidence or presenting as an adrenal crisis, reported via the British Paediatric Surveillance Unit (BPSU) from September 2020 to September 2022.
Results: Over a 25-month period, 190 reports of symptomatic GC-induced AS/adrenal crisis were made, of which 22 were confirmed cases: 18 AS and 4 adrenal crises.
J Clin Med
January 2025
Department of Internal Medicine and Medical Therapeutics, University of Pavia Medical School, 27100 Pavia, Italy.
Chronic obstructive pulmonary disease (COPD) is among the most relevant comorbidity associated with lung cancer. The advent of innovative triple treatment approaches for COPD has significantly improved patients' quality of life and outcomes. Few data are available regarding the impact of triple inhaler therapy on patients featuring COPD and lung cancer.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!